A retrospective study comparing outcomes of relapsing-remitting multiple sclerosis patients treated either with COPAXONE or high-dose interferon beta-1a demonstrated that patients continuously treated ...
An estimated 2.5 million people suffer from multiple sclerosis (MS) worldwide—less than 0.04% of the global population. However, the epidemiology of the disease appears to be undergoing dramatic ...
Rebif is used to treat multiple sclerosis and clinically isolated syndrome. It can interact with certain monoclonal antibodies like alemtuzumab and ozanimod, increasing the risk of infection. Drinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results